So if I'm understanding correctly — the next generation of treatments could include:

• GLP-1 alone (semaglutide — current)
• GLP-1 + GIP dual agonist (tirzepatide — current)
• GLP-1 + amylin dual (CagriSema — coming)
• GLP-1 + GIP + glucagon triple (retatrutide — coming)

How would a doctor decide which one a patient should be on? Is more pathways always better?

Great question. More pathways isn't always better — it's about matching the right mechanism to the right patient. Here's how I think the treatment landscape will eventually stratify:

• GLP-1 monotherapy (semaglutide, oral orforglipron): First-line for most patients. Well-characterized, proven CV benefit, available oral options.
• GLP-1/GIP dual (tirzepatide): For patients needing more weight loss, or with T2D where both GLP-1 and GIP contribute to glucose lowering.
• GLP-1/amylin (CagriSema): For patients with strong hunger/craving phenotype where dual satiety pathway engagement is beneficial. Possibly better for patients with strong hedonic eating patterns.
• GLP-1/GIP/glucagon triple (retatrutide): For patients with MASH/liver disease, or those needing maximum weight loss (BMI 40+). The glucagon component specifically benefits hepatic fat metabolism.

This is speculative, and we don't have biomarkers to predict response to different mechanisms yet. But precision obesity medicine — matching the drug mechanism to the patient phenotype — is where the field is heading.

Well articulated. The REDEFINE program will be a defining data package (pun intended) for CagriSema. REDEFINE-1 topline results are encouraging but we need the full publication with subgroup analyses, body composition data, and metabolic parameters.

For anyone following the field: Novo Nordisk's investor day presentations provide good overviews of the REDEFINE timeline. All Phase 3 trials should report by 2026-2027, with potential FDA approval in 2027-2028 if data are positive. We'll update this thread as publications emerge.